Virion Therapeutics LLC - Providence Business News

OCEAN BIOMEDICAL Inc. is expanding into the energy and digital-asset sectors while announcing it has been delisted on the Nasdaq exchange and a founding member has resigned from its board of directors, according to its filing with the U.S. Securities and Exchange Commission on April 22.

SEC filing of the week: Ocean Biomedical expands into energy, digital...

Economic Activity 04/25/2025

PROVIDENCE – Ocean Biomedical Inc. is expanding into the energy and digital-asset sectors while announcing it has been delisted on the Nasdaq Stock Market...

SEC filing of the week: Ocean Biomedical’s loss narrows to $9.4M...

Economic Activity 04/11/2025

PROVIDENCE – Ocean Biomedical Inc. ended 2024 with a loss of $9.4 million compared to the $114.4 million deficit the company reported the year...

Ocean Biomedical reports ‘highly compelling’ results in first clinical trial

Technology 11/28/2023

PROVIDENCE – Ocean Biomedical Inc., working with joint venture partner Virion Therapeutics LLC, said earlier this month that it saw positive results in its...

Ocean Biomedical enters first in-human clinical trial

Health Services 10/13/2023

PROVIDENCE – Ocean Biomedical, a biopharmaceutical company launched out of Brown University, is entering its first in-human clinical trial with Virion Therapeutics LLC, a...